التفاصيل البيبلوغرافية
| العنوان: |
Factors that predict glycaemic response to sodium‐glucose linked transporter (SGLT) inhibitors. |
| المؤلفون: |
Harding, Amy L., Bediaga, Naiara, Galligan, Anna, Colman, Peter G., Fourlanos, Spiros, Wentworth, John M. |
| المصدر: |
Internal Medicine Journal; Apr2021, Vol. 51 Issue 4, p515-519, 5p |
| مصطلحات موضوعية: |
SODIUM-glucose cotransporters, GLYCOSYLATED hemoglobin, BIOMARKERS, FASTING, BLOOD pressure, ALBUMINS, GLOMERULAR filtration rate, UREA, CONFIDENCE intervals, BODY weight, CLINICAL trials, GLYCEMIC control, URINATION disorders, URINARY tract infections, INDIVIDUALIZED medicine, TYPE 2 diabetes, TREATMENT effectiveness, DESCRIPTIVE statistics, URINALYSIS, ELECTROLYTES, GLUCOSE, LONGITUDINAL method, CREATININE, OUTPATIENT services in hospitals, EVALUATION |
| مستخلص: |
Aim: To determine the clinical and biochemical variables associated with change in HbA1c in patients with type 2 diabetes who start sodium‐glucose linked transporter (SGLT) inhibitor therapy. Methods: We performed a prospective cohort study (ACTRN12616000833460) of 48 adults (30 male, 18 female) with type 2 diabetes who attended a tertiary hospital diabetes clinic. Fasting serum and urine samples, collected during clinic visits prior to and at 1, 12 and 24 weeks after commencing SGLT inhibitor treatment, were analysed for HbA1c, electrolytes, urea, creatinine and glucose. Results: After 12 weeks, SGLT inhibitor therapy was associated with respective median (97% CI) decreases in weight, blood pressure, HbA1c and urine albumin/creatinine ratio of 3.0 (1.7–3.4) kg, 8 (2–16)/4 (3–9) mmHg, 6 (3–14) mmol/mol and 0.69 (0.18–1.8) mg/mmol. These effects persisted to 24 weeks. Urinary frequency and genitourinary infection were common adverse effects. Baseline HbA1c and eGFR independently predicted ΔHbA1c at 12 weeks whereas only baseline HbA1c independently predicted ΔHbA1c at 24 weeks. Urinary fractional glucose excretion and change in fasting glucose 1 week after starting SGLT inhibitor did not contribute to prediction of glycaemic response. Conclusions: SGLT inhibitor therapy in a hospital clinic setting was associated with clinical improvements comparable to those observed in clinical trials but with higher incidence of genitourinary side‐effects. Baseline HbA1c and eGFR, but not urine fractional glucose excretion, predicted glycaemic response. [ABSTRACT FROM AUTHOR] |
|
Copyright of Internal Medicine Journal is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
